Serotonin 2A (5-HT2A) receptors and dopamine D2 receptors are intimately related to the physiology and pathophysiology of neuropsychiatric disorders. A large number of studies have reported the effectiveness of psychotropic agents targeting 5-HT2A and D2 receptors in these disorders. In addition to the individual functions of these receptors, the interaction between the two neurotransmitter systems has been studied in the living brain. However, little is known about their regional relationship in individual human brains. We investigated regional relationships between 5-HT2A and D2 receptors using positron emission tomography (PET) and a bicluster analysis of the correlation matrix of individual variation in the two receptor densities to identify groups of distinctive regional correlations between the two receptors.
Seven healthy volunteers underwent PET scans with [18F]altanserin and [11C]FLB 457 for 5-HT2A and D2 receptors, respectively. As a measure of receptor density, a binding potential (BP) was calculated from PET data for 76 cerebral cortical regions. A correlation matrix was calculated between the binding potentials of [18F]altanserin and [11C]FLB 457 for those regions. The regional relationships were investigated using a bicluster analysis of the correlation matrix with an iterative signature algorithm.
We identified two clusters of regions. The first cluster identified a distinct profile of correlation coefficients between 5-HT2A and D2 receptors, with the former in regions related to sensorimotor integration (supplementary motor area, superior parietal gyrus, and paracentral lobule) and the latter in most cortical regions. The second cluster identified another distinct profile of correlation coefficients between 5-HT2A receptors in the bilateral hippocampi and D2 receptors in most cortical regions.
The observation of two distinct clusters in the correlation matrix suggests regional interactions between 5-HT2A and D2 receptors in sensorimotor integration and hippocampal function. A bicluster analysis of the correlation matrix of these neuroreceptors may be beneficial in understanding molecular networks in the human brain.
Citation: Ishii T, Kimura Y, Ichise M, Takahata K, Kitamura S, Moriguchi S, et al. (2017) Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain. PLoS ONE 12(12): e0189318. https://doi.org/10.1371/journal.pone.0189318
Editor: Kewei Chen, Banner Alzheimer’s Institute, UNITED STATES
Received: July 7, 2017; Accepted: November 22, 2017; Published: December 8, 2017
Copyright: © 2017 Ishii et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Serotonin 2A (5-HT2A) receptors and dopamine D2 receptors are intimately related to the physiology and pathophysiology of neuropsychiatric disorders. Psychotropic agents targeting 5-HT2A and D2 receptors are used in the treatment of these disorders [1,2]. In addition to the individual functions of the 5-HT2A and D2 receptors, the interactions between 5-HT2A and D2 receptors have been studied in the living brain. For example, a 5-HT2A receptor agonist, 2,5-dimethoxy-4-iodoamphetamine, is reported to increase extra-synaptic concentrations of dopamine and noradrenaline in the rat frontal cortex . In addition, a 5-HT2A receptor antagonist modulates dopamine release in rat brain . Moreover, a 5-HT2A receptor inverse agonist, pimavanserin, potentiates haloperidol-induced dopamine release in the medial prefrontal cortex in rats . In humans, a 5-HT2A receptor agonist, psilocybin, induces schizophrenia-like psychosis  and alters dopamine release [7,8]. These findings suggest that both dopaminergic and serotonergic neurotransmitter systems jointly contribute to the development of psychiatric symptoms.
Many studies have investigated interactions between the two neurotransmitter systems using pharmacological and genetic techniques. These studies have usually examined the whole brain. However, little is known regarding the regional relationships between the two neurotransmitter systems in individual human brains. Another line of evidence comes from the finding that the genes for 5-HT2A and D2 receptors concomitantly modulate physiological prefrontal efficiency during working memory, as assessed using functional magnetic resonance imaging (fMRI) and the response to antipsychotics . However, we do not as yet have any regional information regarding this interaction.
To investigate the regional interactions between the two neurotransmitter systems in the cortex, we investigated the distributions and densities of the two receptor types in the same individuals. As the distributions and densities of the two receptor types are influenced by many factors, such as gene polymorphisms and functional adaptation, they may reflect functional relationships between the two neurotransmitter systems. We hypothesized that the individual variations of 5-HT2A receptor density in cortical regions are correlated with those of D2 receptor density in multiple cortical regions, and that regions sharing a specific interaction between the two neurotransmitter systems would share distinct regional correlation profiles. Using positron emission tomography (PET), we investigated regional relationships of density between 5-HT2A and D2 receptors and analyzed the profiles of regional correlation in healthy individuals.
Materials and methods
Seven healthy male volunteers (age: 23 ± 1.5 years, weight: 66 ± 8.1 kg, mean ± standard deviation [SD]) were recruited. The participants were recruited from the registered volunteers in our research institute from December in 2010 to August in 2014. Among twelve volunteers approached, seven participants agreed to participate in the current study. No subject dropped out from the study. All of the subjects were right-handed and had no current or past history of smoking. No subjects reported drug abuse, alcohol abuse, or mental illness. Written informed consent was obtained from all subjects. The Ethics and Radiation Safety Committee of the National Institute of Radiological Sciences approved the study protocol. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000013798).
All subjects underwent a 3.0-T MR scan of the brain for anatomical reference. None of the subjects had structural abnormalities. All MRI images were acquired using a MAGNETOM Verio scanner (Siemens AG; Munich, Germany). T1-weighted MR images were acquired using a three-dimensional magnetization-prepared rapid gradient-echo sequence (echo time: 1.9 ms, repetition time: 2,300 ms, flip angle: 9, field of view: 250 mm, acquisition matrix: 256 × 256, slice thickness: 1 mm).
Each subject underwent two PET scans to visualize serotonin 5-HT2A and dopamine D2 receptors. All of the PET scans were performed using an Eminence SET-3000 GCT/X PET scanner (Shimadzu; Kyoto, Japan). For evaluation of density of D2 receptors, a 90-minute dynamic PET scan was performed after an injection of [11C]FLB 457. The scan protocol consisted of 35 frames and lasted 90 minutes. The injected dose and specific activity were 235 ± 4.8 MBq and 220 ± 68 GBq/μmol at the time of injection, respectively. For evaluation of density of serotonin 5-HT2A receptors, a 90-minute dynamic PET scan was performed after an injection of [18F]altanserin. The scan protocol consisted of 33 frames and lasted 90 minutes. The injected dose and specific activity were 191 ± 5.2 MBq and 153 ± 73 GBq/μmol at the time of injection, respectively. Each PET scan was preceded by a transmission scan for attenuation correction using a 137Cs source. A head holder was used to minimize head movement. The two scans were performed on separate days (average interval: 20.6 ± 13 months, range 3.4–40.0 months).
For the [18F]altanserin PET, arterial blood samples were obtained manually 33 times after the injection of the radioligand to obtain an arterial input function. Each blood sample was centrifuged to obtain plasma and blood cell fractions, and the concentrations of radioactivity in whole blood and plasma were measured. The fractions of the parent compound and its radiometabolites in plasma were determined using high-performance liquid chromatography from 6 samples for each subject.
Brain image analysis
All PET images were spatially normalized to the standard anatomic orientation. First, all dynamic images were corrected for head motion using PMOD (version 3.6, PMOD Technologies, Zürich, Switzerland). Second, T1-weighted MR images were coregistered to the corresponding PET images. Third, the MR images were spatially normalized and segmented into gray matter, white matter, and cerebrospinal fluid using SPM8 (Wellcome Institute of Neurology, University College of London, UK). Finally, all PET images were spatially normalized to the standard anatomic orientation (the Montreal Neurological Institute 152 standard space; Montreal Neurological Institute; Montreal, QC, Canada) based on the transformation of the MR images.
Calculation of regional 5-HT2A receptor density
A multi-linear analysis  with an arterial input function (concentration of the parent compound in plasma) was used to estimate total distribution volume (VT). VT is equal to the ratio of the concentration of the radioligand in the tissue to that in the plasma at equilibrium. The time point t* after which the model became linear was set to 20 minutes for the multi-linear analysis. Binding potential (BPP) was then calculated as follows: BPP = VT—VND, where VND is the total distribution volume in the cerebellum as reference tissue and 5-HT2A receptor density is negligible, as indicated by autoradiography studies in humans and an in vivo displacement study in monkeys [11–13].
Calculation of regional D2 receptor density
The multi-linear reference tissue model method (MRTM2) was used to estimate binding potential (BPND) of [11C]FLB 457 . The time point t* was set to 1 minute for MRTM2. The parameter k2′, which is an efflux constant for the reference region, was calculated for each subject using k2′ from the thalamus, which is a low-noise region, using MRTM. We used the cerebellum as reference tissue because D2 receptor density is negligible in this region as indicated by an autoradiography study in human and an in vivo displacement study in monkeys [13,15].
Regions of interest
Regions of interest (ROIs) were defined based on Automated Anatomical Labeling . For each subject, the regions were intersected with individual gray matter images. The intersected ROIs were applied to the parametric PET images to extract binding potentials for each region. We selected seventy-six ROIs to analyze regional BP values in the cerebral cortex. The striatum was excluded from the current analysis because D2 receptor density in the striatum is too high to quantify using [11C]FLB 457. All kinetic analyses were performed using PMOD (version 3.6, PMOD Technologies, Zürich, Switzerland).
Correlation and clustering analyses
Procedures of correlation and clustering analyses were summarized in a diagram (Fig 1A–1D). Based on data from the seven subjects, we calculated a correlation matrix of Spearman’s rank correlation coefficients between the BPP of [18F]altanserin and BPND of [11C]FLB 457 for the 76 regions (the two parameters are referred to as BP hereafter). The relationships between the distributions of the 5-HT2A and D2 receptors were investigated using unsupervised biclustering of regions on the correlation matrix with an iterative signature algorithm (ISA)  implemented in the biclustering analysis toolbox (Eidgenössische Technische Hochschule, Zürich). This biclustering method (simultaneous two-directional clustering) identifies regions of distinct regional profiles of correlation coefficients for 5-HT2A and D2 receptors by optimizing thresholds described previously [17,18]. In brief, we determined biclusters that were initially selected from 50 random starting points across the rows and columns of the correlation matrix and were iteratively refined to satisfy a given set of thresholds using the following steps (Fig 1C). Step 1: The ISA initially started with a set of random regions (R(n), n = 0) selected from all of the rows. Step 2: An evaluation score for the columns (Scorecolumn) was calculated as an average of correlation coefficients in the extracted column multiplied by the score for the row (Scorerow). Step 3: A set of columns (C(n), n = 0) was extracted from all columns so that the Scorecolumn was larger than a preset threshold for the column. Step 4: Scorerow was re-calculated as an average of the correlation coefficients in the extracted rows multiplied by Scorecolumn. Step 5: A set of rows (R(n), n = 1) was extracted from all rows so that Scorerow was larger than a preset threshold for the row. Finally, steps 2 to 5 were repeated until convergence (R(n) = R(n+1)) was achieved. R(n) and C(n) were then reported as clusters. We then optimized the thresholds for the identification of the biclusters . The optimization of the thresholds attempted to rigorously extract biclusters with as high a number of regions as possible without overlapping regional pairs among the biclusters. The optimized thresholds for rows and columns were 1.4 and 2.0, respectively.
A) Individual binding potential (BP) values of [18F]altanserin and [11C]FLB 457 were extracted for 76 regions in seven subjects. B) A correlation matrix of correlation coefficients was calculated between BP values of [18F]altanserin and [11C]FLB 457 for the 76 regions. An example of a scatter diagram (top) shows the correlation between BP values of [11C]FLB 457 in the left superior parietal gyrus (region #53) and the BP values of [18F]altanserin in the left fusiform gyrus (region #49). C) Biclustering was performed on the matrix using an iterative signature algorithm (see Methods). R(n) and C(n): sets of rows and columns at the nth iteration, Scorerow and Scorecolumn: the evaluation scores for the rows and columns, Thr.row and Thr.column: thresholds for the rows and columns. D) Two clusters of regions were identified (see Results).
5-HT2A receptors were distributed in widespread regions of cerebral cortex, while D2 receptors had varying densities in the 76 cerebral cortical regions (Fig 2). The mean regional BP values of 5-HT2A receptors were between 0.8 and 2.0, being relatively low in the hippocampus (0.83 ± 0.34), paracentral lobule (1.16 ± 0.33), and parahippocampus (1.17 ± 0.35) (Fig 2). In contrast, the mean BP values of D2 receptors, varied among the different regions. The BP values were high in the hippocampus (1.53 ± 0.25), parahippocampus (1.34 ± 0.24), and temporal cortex (1.23 ± 0.36) and low in the paracentral lobule (0.36 ± 0.19), occipital lobe (0.43 ± 0.20), and frontal cortex (0.51 ± 0.21) (Fig 2). The observed regional distributions of 5-HT2A and D2 receptors were consistent with the findings of previous postmortem  and PET studies [20–22].
Mean BP values for [18F]altanserin for 5-HT2A receptors (blue) and [11C]FLB 457 for D2 receptors (red) were plotted for 76 cerebral regions. The numbers represent regions defined in Table 1. Raw data of BP values is available as supporting information (S1 File).
The bicluster analysis of the correlation matrix of the 76 regions (Fig 3), identified two clusters of regions (Figs 4 and 5), which were characterized by distinctive profiles of regional 5-HT2A and D2 receptor density correlations pairs. The two clusters were mutually exclusive, and they resulted to consist of positive correlation coefficients.
A correlation matrix was generated based on Spearman’s correlation coefficients (r values) between individual binding potential values of [18F]altanserin for 5-HT2A receptors (columns) and [11C]FLB457 for D2 receptors (rows) in 76 regions. The numbers represent regions defined in Table 1. Raw data of the matrix is available as supporting information (S2 File).
(A) The first cluster consisted of correlations between 5-HT2A receptor binding potentials (BP) for the frontal and parietal cortices and D2 receptor BP for broad cortical regions (71 regions). Regions in the first cluster (inside the yellow boxes): supplementary motor area (19, 20), superior parietal gyrus (53, 54), paracentral lobule (63, 64); regions adjacent to the first cluster (outside of the yellow boxes): inferior parietal gyrus (55, 56), postcentral gyrus (51, 52), precuneus (61, 62), and superior frontal gyrus (3, 4). (B) The second cluster consisted of correlations between 5-HT2A receptor BP for the bilateral hippocampi and D2 receptor BP for broad regions (73 regions) in the cerebral cortex. Regions in the second cluster (inside the yellow boxes): hippocampus (33, 34), regions adjacent to the second cluster (outside of the yellow boxes): parahippocampus (35, 36) and fusiform (49, 50).
(A) Regions for 5-HT2A receptors and those for D2 receptors in the first cluster. (B) Regions for 5-HT2A receptors and those for D2 receptors in the second cluster.
The first cluster consisted of regional pairs with positive correlation coefficients between 5-HT2A receptors in the supplementary motor area, superior parietal gyrus, and paracentral lobule and D2 receptors in broad cortical regions (r = 0.40 ± 0.17 [mean ± SD], Figs 4A and 5A). 5-HT2A receptors in the adjacent regions (inferior parietal gyrus, postcentral gyrus, precuneus, and superior frontal gyrus), which were not extracted in the first cluster, had quite different profiles of correlation coefficients against D2 receptors in the broad cortical regions. These regions included regional pairs with negative correlation coefficients, as indicated by the green boxes. D2 receptors in the five regions (orbital part of the bilateral middle frontal gyri, left superior frontal gyrus, right inferior frontal gyrus, and left temporal pole in the middle temporal gyrus) were not extracted into the first cluster.
The second cluster consisted of regional pairs with positive correlation coefficients between 5-HT2A receptors in the bilateral hippocampi and D2 receptors in broad cortical regions (r = 0.48 ± 0.15, mean ± SD, Figs 4B and 5B). 5-HT2A receptors in the adjacent regions (parahippocampus and fusiform), which were not extracted in the second cluster, had negative correlation coefficients against D2 receptors in the broad cortical regions. D2 receptors in the temporal pole in the superior and middle temporal gyri and the parahippocampus were not extracted into the second cluster.
In this study, we identified two clusters of regions with distinct regional profiles of correlation coefficients between 5-HT2A receptors and D2 receptors in the matrix. The first cluster suggests that 5-HT2A receptors in the regions of sensorimotor integration (supplementary motor area, superior parietal gyrus, and paracentral lobule) may have interactions with D2 receptors in the broad cortical regions. The second cluster indicates that 5-HT2A receptors in the bilateral hippocampi may have other interactions with D2 receptors in the broad cortical regions.
Individual variations in the densities of the receptors may be caused by their baseline expressions and adaptation . Under the situation where gene expression and adaptation interact and/or are regulated simultaneously in two separated regions, the densities of receptors may correlate between the two regions. This would suggest functional associations between the two receptor types in the two regions. In the human cortex, 5-HT2A receptors are mainly expressed post-synaptically on glutamatergic pyramidal neurons, cholinergic neurons, and gamma-aminobutyric acid (GABA)ergic interneurons [24,25]. In contrast, D2 receptors are mainly expressed on presynaptic dopaminergic neurons and postsynaptic GABAergic interneurons . The functional associations between the two receptors in the separate regions may reflect the direct and/or indirect projections of those neurons from the origins of the serotonin and dopamine systems, which are the raphe nucleus and the ventral tegmental area, respectively. In this study, we performed a bicluster analysis of the correlation matrix of individual variation in the two receptor densities. We identified distinct regional correlation profiles between the two receptor types and extracted clusters that reflected functional interrelationships between the two neurotransmitter systems in the extracted regions.
In the first cluster, the extracted regions containing 5-HT2A receptors were related to sensorimotor integration. The supplementary motor area is involved in the integration of motor functions [27,28] and the superior parietal gyrus is involved in the integration of somatosensory and visual functions . The paracentral lobule integrates motor and sensory functions with motor and sensory innervation of the contralateral lower extremity . 5-HT2A receptors are involved in the above sensorimotor processes, which may be disrupted in schizophrenia and affected by hallucinogens [31,32]. As a modification of the dopamine system by D2 receptors can also affect sensorimotor processing , the current cluster may indicate regions with interactions related to sensorimotor integration between the two neurotransmitter systems.
In the second cluster, the extracted regions containing 5-HT2A receptors were the bilateral hippocampi. The hippocampus is a key region in the brain for memory processing. 5-HT2A receptor activation in the hippocampus facilitates the consolidation of object memory [34, 35], fear learning , and long-term memory . As the function of the mesocortical dopamine pathway is not limited to executive functions such as working memory, but also involves aversion and learning , our results may reflect the interactions between the two neurotransmitter systems in memory functions.
The results of clustering analysis, which was carried out using an iterative signature algorithm, depend on the optimization of thresholds. In this study, we optimized thresholds based on a standard method reported previously . We used the numbers of extracted columns, extracted rows and identified clusters as parameters of the optimization. These parameters were plotted graphically for various threshold values of rows and columns. Threshold values leading to the retention of as much coverage and rigidity as possible were chosen in a fixed range based on graphic judgments. The numbers of the extracted clusters did not change when the thresholds were altered within their ranges. This reflects the robustness of the results to variation in the thresholds. However, a small number of regions containing D2 receptors in the extracted clusters varied in the optimization process used for the thresholds. In clusters 1 and 2, most of the cortical regions were included in the clusters at the D2 receptor side of regional pairs, while 3 to 5 regions were excluded from the clusters. As the numbers of regions excluded from the clusters were not stable when we changed the thresholds in the narrowed range, we did not consider the regions excluded from the clusters at the D2 receptor side of regional pairs as significant.
The small sample size is a limitation of the current study, and any generalization of our findings needs to be approached with caution. An additional study with a larger sample size is needed to replicate and confirm the current findings. Another limitation is that our study included only male subjects. Any potential effect of gender on our current findings needs to be addressed in future studies. Finally, the large time difference between two PET scans is also a limitation of the current study. However, we believe the effects of the PET scan time difference on the results of clustering should be minimum if any for the following reasons. Previous PET studies have shown that BP of [11C]FLB 457 changes slowly with aging (10% decrease per decade) , and BP of [18F]altanserin also changes slowly with aging (less than 10% decrease per decade) . The PET scan time differences in our study were between 3 and 40 months, which would correspond to potential BP changes if any due to the scan time differences are within 5%, being less than the test-retest variability of the PET measurements of usually 10% or more.
Our approach may be useful not only for the analysis of the interaction between different brain system, but also for understanding dysfunction in neurotransmitter systems. For example, in patients with the obsessive compulsive disorder, a significant reduction in 5-HT2A receptor density is observed in the cortex, including the associative area . In addition, antipsychotic augmentation is effective in some patients refractory to serotonin reuptake inhibitors . In patients with Alzheimer’s disease, 5-HT2A receptor density was reduced in most neocortical areas . In rodent models, the Alzheimer’s-like neuropathology and memory were associated with a reduction of hippocampal 5-HT2A receptor expression . In aging, 5-HT2A receptor density slowly decreases . Since those studies did not investigate the density of dopamine D2 receptors in the same subjects, it is not possible to assess the alteration of the interaction between the two neurotransmitter systems in such diseases or aging. However, our study will provide an opportunity to consider simultaneous observation of the two neurotransmitter systems to see their potential interactions in the regions in clusters in future studies. It would be helpful to know whether interactions between the two neurotransmitter systems in the extracted cluster regions contribute to such disorders.
In conclusion, we identified two regional clusters that may suggest regional interactions between 5-HT2A and D2 receptors in sensorimotor integration and hippocampal functions. Bicluster analysis of the correlation matrix of neuroreceptors may be beneficial in understanding molecular networks in the human brain.
S1 File. Regional binding potential (BP) values for 5-HT2A and D2 receptors in cerebral cortical regions.
An excel file contains BP vales of [18F]altanserin for 5-HT2A receptors and [11C]FLB 457 for D2 receptors in cerebral cortical regions.
S2 File. Correlation matrix of regions containing 5-HT2A and D2 receptors.
An excel file contains Spearman’s correlation coefficients (r values) between individual binding potential values of [18F]altanserin for 5-HT2A receptors (columns) and [11C]FLB 457 for D2 receptors (rows) in 76 regions.
We thank the radiology technologists in the PET department and the members of the clinical neuroimaging team for their support in the PET scans, Kazuko Suzuki and Shizuko Kawakami for their assistance as clinical coordinators, Hiromi Sano for her support in the MRI scans, and the staff of the molecular probe program for radioligand synthesis and metabolite analysis. Moreover, we thank Sayaka Mizutani (Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology) for her support in the clustering analysis.
- 1. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28: 156–165. pmid:18344725
- 2. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14: 197–206. pmid:19407731
- 3. Gobert A, Millan MJ. Serotonin 5-HT2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology. 1999;38: 315–317. pmid:10218874
- 4. Egerton A, Ahmad R, Hirani E, Grasby PM. Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology. 2008;200: 487–496. pmid:18597077
- 5. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology. 2005;183: 144–153. pmid:16220333
- 6. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9: 3897–3902. pmid:9875725
- 7. Kimura Y, Maeda J, Yamada M, Takahata K, Yokokawa K, Ikoma Y, et al. Measurement of psychological state changes at low dopamine transporter occupancy following a clinical dose of mazindol. Psychopharmacology. Psychopharmacology. 2017;234: 1–6.
- 8. Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20: 424–433. pmid:10192823
- 9. Blasi G, Selvaggi P, Fazio L, Antonucci LA, Taurisano P, Masellis R, et al. Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics. Neuropsychopharmacology. 2015;40: 1600–1608. pmid:25563748
- 10. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. Journal of Cerebral Blood Flow & Metabolism. 2002;22: 1271–1281.
- 11. Kroll T, Elmenhorst D, Matusch A, Wedekind F, Weisshaupt A, Beer S, et al. Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models. Mol Imaging Biol. 2013;15: 456–467. pmid:23456885
- 12. Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbøl S, et al. Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach. Journal of Cerebral Blood Flow & Metabolism. 2003;23: 985–996. pmid:12902843
- 13. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, et al. In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage. 2008;42: 306–314. pmid:18511303
- 14. Ichise M, Liow J-S, Lu J-Q, Takano A, Model K, Toyama H, et al. Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain. Journal of Cerebral Blood Flow & Metabolism. 2003;23: 1096–1112. pmid:12973026
- 15. Asselin M-C, Montgomery AJ, Grasby PM, Hume SP. Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region. Journal of Cerebral Blood Flow & Metabolism. 2007;27: 378–392. pmid:16736043
- 16. Tzourio-Mazoyera N, Landeaub B, Papathanassioua D, Crivelloa F, Etarda O, Delcroixa N, et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain. NeuroImage. 2002;15: 273–289. pmid:11771995
- 17. Ihmels J, Bergmann S, Barkai N. Defining transcription modules using large-scale gene expression data. Bioinformatics. 2004;20: 1993–2003. pmid:15044247
- 18. Iskar M, Zeller G, Blattmann P, Campillos M, Kuhn M, Kaminska KH, et al. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding. Molecular Systems Biology. 2013;9: 662. pmid:23632384
- 19. Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Research. 1995;676: 157–168. pmid:7796165
- 20. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, et al. A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. NeuroImage. 2004;21: 1105–1113. pmid:15006678
- 21. Ito H, Takahashi H, Arakawa R, Takano H, Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. NeuroImage. 2008;39: 555–565. pmid:17962043
- 22. Savli M, Bauer A, Mitterhauser M, Ding Y-S, Hahn A, Kroll T, et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage. 2012;63: 447–459. pmid:22789740
- 23. Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. International Journal of Genomics. 2014;2014: 970607–970615. pmid:25180174
- 24. Morilak DA, Somogyi P, Lujan-Miras R, Ciaranello RD. Neurons expressing 5-HT2 receptors in the rat brain: neurochemical identification of cell types by immunocytochemistry. Neuropsychopharmacology. 1994;11: 157–166. pmid:7865097
- 25. Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex. 2004;14: 1100–1109. pmid:15115744
- 26. Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci USA. 2001;98: 1964–1969. pmid:11172059
- 27. Goldberg G. Supplementary motor area structure and function: review and hypotheses. Behavioral and Brain Sciences. 1985;8: 567–588.
- 28. Tanji J. The supplementary motor area in the cerebral cortex. Neuroscience Research. 1994;19: 251–268. pmid:8058203
- 29. Wolpert DM, Goodbody SJ, Husain M. Maintaining internal representations: the role of the human superior parietal lobe. Nat Neurosci. 1998;1: 529–533. pmid:10196553
- 30. Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013;23: 852–864. pmid:23176747
- 31. Padich RA, McCloskey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition. Psychopharmacology (Berl). 1996;124: 107–116.
- 32. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53: 439–452. pmid:17270739
- 33. Mansbach RS, Geyer MA, Braff DL. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 1988;94: 507–514. pmid:3131796
- 34. Zhang G, Cinalli D, Stackman RW. Effect of a hallucinogenic serotonin 5-HT2A receptor agonist on visually guided, hippocampal-dependent spatial cognition in C57BL/6J mice. Hippocampus. 2017;27: 558–569. pmid:28176400
- 35. Zhang G, Stackman RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol. 2015;6: 225. pmid:26500553
- 36. Bauer EP. Serotonin in fear conditioning processes. Behavioural Brain Research. 2015;277: 68–77. pmid:25078294
- 37. Meneses A. Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: Short- and long-term memory. Behavioural Brain Research. 2007;184: 81–90. pmid:17692935
- 38. Boureau Y-L, Dayan P. Opponency revisited: competition and cooperation between dopamine and serotonin. Neuropsychopharmacology. 2011;36: 74–97. pmid:20881948
- 39. Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, Kishimoto T, et al. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci. 2001;69: 1079–1084. pmid:11508650
- 40. Moses-Kolko EL, Price JC, Shah N, Berga S, Sereika SM, Fisher PM, et al. Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology. 2011;36: 2729–2740. pmid:21849982
- 41. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry. 2006;11: 622–632. pmid:16585942
- 42. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging. 2008;29: 1830–1838. pmid:17544547
- 43. Christensen R, Marcussen AB, Wörtwein G, Knudsen GM, Aznar S. Aβ(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Exp Neurol. 2008;210: 164–171. pmid:18053988